Strategic Partnerships
At Protalix, we understand the unique challenges of developing therapeutics for rare diseases. We are dedicated to accelerating progress for patients, but we know this requires a collaborative approach.
Tailored Partnerships for Innovative Protein Therapeutics
We actively seek partnerships with organizations that share our vision of a future free from the burden of rare diseases. We also recognize that every partnership is unique. Working closely with each collaborator, we endeavor to define a structure that best serves our shared goals in developing protein therapeutics. This may involve:
& Development
Combining expertise and resources to tackle specific scientific challenges associated with protein engineering, bioavailability, and efficacy of therapeutics for rare diseases. This includes leveraging our ProCellEx® platform for development of novel protein therapeutic candidates.
Collaboration
Partnering to design, conduct, and analyze clinical trials efficiently, drawing on expertise in rare disease protocols.
& Marketing
Partnering with companies with expertise in navigating regulatory hurdles, securing market access, and developing targeted marketing strategies in the rare disease space. This ensures patients can access these life-changing therapies as quickly as possible.
The Power of Collaboration
By fostering strong, collaborative partnerships, we can:
Innovative Therapies
By combining expertise and resources we can bring new protein therapeutics and other protein therapeutics to patients faster.
& Costs
Collaboration allows us to share the burden of development costs and scientific challenges.
in Rare Diseases
Partnering with patient advocacy groups and clinical trial networks with experience in rare diseases allows us to connect with a wider range of patients and accelerate clinical trials.
CURRENT PARTNERSHIPS:
Pfizer
Pfizer Inc. is our global partner for the commercialization of Elelyso®, excluding Brazil.
Our collaborative relationship with Pfizer was initiated in November 2009 and restated in October 2015. Under the arrangement, we granted to Pfizer the exclusive right to commercialize taliglucerase alfa for the treatment of Gaucher disease for all markets outside of Brazil. Protalix and Pfizer agreed to collaborate in the clinical development of taliglucerase alfa and in the regulatory process that resulted in the ultimate approvals of Elelyso® for the treatment of patients with Gaucher disease. Protalix manufactures the Elelyso® drug substance for commercial purposes.
CHIESI GLOBAL RARE DISEASES
Chiesi Global Rare Diseases, a business unit of the Chiesi Group, is our global partner for the commercialization of Elfabrio®.
We first entered into a collaboration arrangement with Chiesi Farmaceutici S.p.A. in 2017, which was later expanded in 2018. As part of these arrangements, we granted to Chiesi the exclusive right to commercialize pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease for all markets. Protalix and Chiesi agreed to collaborate in the clinical development of pegunigalsidase alfa and in the regulatory process that resulted in the ultimate approvals of Elfabrio® for the treatment of adult patients with Fabry disease. Protalix manufactures the Elfabrio® drug substance for commercial purposes as well as for post-approval clinical studies sponsored by Chiesi.
Chiesi Global Rare Diseases was established to deliver innovative therapies and solutions for people affected by rare diseases.
Fundação Oswaldo Cruz
Fundação Oswaldo Cruz, or Fiocruz, is our partner for the commercialization of alfataliglicerase (Elelyso®) in Brazil. Fiocruz is an arm of the Brazilian Ministry of Health. We sell alfataliglicerase to Fiocruz at negotiated prices.
